FDA Approved Ameluz Gel for Skin Cancer Treatment
The therapy uses red-light treatment to target superficial basal cell carcinoma in adults.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Would you choose a non-surgical light therapy over surgery if diagnosed with skin cancer?
On Sept. 14, 2026, the FDA approved the use of Ameluz gel in combination with red-light photodynamic therapy to treat superficial basal cell carcinoma. The treatment involves applying a specialized gel followed by light exposure to trigger a targeted chemical reaction against cancerous lesions.
Why it matters
Left untreated, basal cell carcinoma can progressively grow into surrounding tissue and cause significant physical damage. This non-invasive approval provides a new option for patients to address these lesions while maintaining cosmetic integrity.
In a phase 3 trial of 187 adults, 66% of patients achieved complete lesion clearance 12 weeks after treatment compared to just 5% of those who received a placebo. Furthermore, 89% of patients experienced a good or very good cosmetic outcome.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and drugs.
The details
Patients undergo treatment cycles consisting of two photodynamic therapy sessions performed one to two weeks apart, with a maximum of two cycles allowed. Common side effects reported during clinical examination include stinging, burning, redness, and swelling at the site of application.
Timeline
Sept. 14, 2026: The FDA officially granted approval for Ameluz gel.
12 weeks after treatment: Researchers conducted the clinical evaluation to confirm lesion clearance.
Health Landscape
This approval follows the established standards set by the FDA's regulatory framework for photodynamic therapy regarding safety and efficacy for oncology applications. It marks a continued shift toward non-surgical, site-specific treatment modalities for localized skin malignancies.
Patients diagnosed with superficial basal cell carcinoma now have a non-surgical alternative that offers high clearance rates with minimal cosmetic impact. Those considering the treatment should discuss the two-cycle protocol and potential side effects like skin stinging or redness with their dermatologist.
The takeaway
This treatment demonstrates that targeted photodynamic therapy can achieve high clearance rates while avoiding the scarring often associated with surgical removal. Patients and providers should continue to monitor the site to ensure results remain durable over the long term.
Further reading
For more information on current treatment standards, visit the Cancer section.
Source note: This article includes information reported by Curetoday.
Live Poll
Would you choose a non-surgical light therapy over surgery if diagnosed with skin cancer?
